- Trial phase
- Approved (marketed); label-expansion programs: Phase 3 (AOSD, Japan) completed; Phase 3 (first-line NSCLC) terminated
- Time to market
- Already marketed: US FDA approval recorded 2009-06-17 (SEC-extracted catalyst data). No new market entry pending per available data; the completed Phase 3 AOSD study (Japan) is a label-expansion candidate whose regulatory outcome was not disclosed in the sources.
- Why 3/10
- No hard, dated catalyst in the next ~12 months: the Phase 3 lung-cancer expansion study (NCT03631199) was terminated, the Phase 3 AOSD study in Japan (NCT04717635) already completed with results in April 2025, and SecBot shows no scheduled PDUFA or pivotal readout for Ilaris, so the score sits at the low end of the approved-drug band (3-5) since Ilaris is also just one small product inside a diversified megacap.
Treat Ilaris as a mature cash-flow product, not a binary, the big upside experiment (first-line lung cancer) was terminated, and no FDA decision is pending. The only share-price-relevant news to watch is Novartis' quarterly reporting (6-K/20-F) for Ilaris sales momentum, any label expansion or divestiture headlines, and broader NVS catalysts like the Phase 3 KRAS-lung-cancer readout (JDQ443) due around August 2026.
Price Chart
Executive Summary
Ilaris (canakinumab, code ACZ885) is Novartis' injectable anti-IL-1β antibody, approved in the US since June 2009 (SEC-extracted FDA approval catalyst) and marketed for rare autoinflammatory diseases. It remains an active development asset, a Phase 3 adult-onset Still's disease study in Japan completed with results in 2025, but its biggest growth bet, adding canakinumab to first-line immunotherapy/chemo for lung cancer, was terminated (673-patient Phase 3). With no pending regulatory decision and Ilaris being a small program inside a ~$156/share diversified pharma, the drug is not a near-term binary for NVS.
How It Works
Canakinumab is a lab-made antibody (a biologic, injected under the skin) that grabs and disables interleukin-1 beta, a protein the immune system uses to signal inflammation. Blocking it calms the runaway inflammation behind several rare autoinflammatory diseases (e.g., periodic fever syndromes) and gout flares; the same mechanism was also tested, unsuccessfully, as an anti-cancer add-on.
Trial Status
Per ingested ClinicalTrials.gov records: a 673-patient Phase 3 study of canakinumab + pembrolizumab + chemo in untreated advanced NSCLC (NCT03631199) was TERMINATED; a Phase 3 study in Japanese adult-onset Still's disease patients (NCT04717635, n=14) COMPLETED with results in April 2025; Phase 2 studies in lung cancer combos (NCT04905316), high-risk former smokers (NCT06038526), and pyoderma gangrenosum (NCT01302795) are all completed.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Ilaris itself in the next ~12 months; watch Novartis quarterly 6-K results for Ilaris sales and any label-expansion or divestiture announcements.
- Company-level context: an unrelated NVS Phase 3 readout (JDQ443 vs docetaxel in KRAS G12C NSCLC, NCT05132075) has an estimated primary completion around August 2026, per ingested trial data.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report